Parkinson's Drug Development en San Francisco

Parkinson's Drug Development image 1
Contacte al anunciante
(617) 455-4188
Contacte al anunciante

With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.


Building on the field's momentum, we are delighted to bring back the 11th Alzheimer's and Parkinson's Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer's, Parkinson's, and related neurological disorders in 2022 and 2023.


URLs:
Tickets: https://go.evvnt.com/1401329-1?pid=6842
Brochure: https://go.evvnt.com/1401329-3?pid=6842


Date and Time: On Tue, Feb 21, 2023 ( 9:00 AM) - Thu, Feb 23, 2023 ( 5:30 PM)


Venue details: Hyatt Centric Fisherman's Wharf San Francisco, 555 North Point Street, San Francisco, California, 94133, United States


Prices:
Conference + Pre-Conference Workshop Day - Drug Developer: USD 4946.00,
Conference + Novel CNS Biomarker Day - Drug Developer: USD 4946.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Pre-Conference Workshop Day - Service Provider Pricing: USD 5846.00,
Conference + Novel CNS Biomarker Day - Service Provider Pricing: USD 5846.00,
Conference Only - Service Provider Pricing: USD 3599.00


Speakers: Rachel Angers Associate Director, Neurodegeneration UCB, Sandra Banack Senior Scientist Brain Chemistry Labs, Habib Baghirov Scientific Lead Roche, Jay Barth Executive Vice President and Chief, Medical Officer Lexeo Therapeutics, Karen He Scientist, Disease Genetics Janssen, Tien Dam Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders Biogen, Cheng Fang Senior Vice President, Research and Development Annovis Bio, Sarah Huntwork-Rodriguez Associate Director, Biomarkers Denali Therapeutics Inc., and more.

Categoría: Eventos ›
Subcategoría: Otros Eventos ›

With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.


Building on the field's momentum, we are delighted to bring back the 11th Alzheimer's and Parkinson's Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer's, Parkinson's, and related neurological disorders in 2022 and 2023.


URLs:
Tickets: https://go.evvnt.com/1401329-1?pid=6842
Brochure: https://go.evvnt.com/1401329-3?pid=6842


Date and Time: On Tue, Feb 21, 2023 ( 9:00 AM) - Thu, Feb 23, 2023 ( 5:30 PM)


Venue details: Hyatt Centric Fisherman's Wharf San Francisco, 555 North Point Street, San Francisco, California, 94133, United States


Prices:
Conference + Pre-Conference Workshop Day - Drug Developer: USD 4946.00,
Conference + Novel CNS Biomarker Day - Drug Developer: USD 4946.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Pre-Conference Workshop Day - Service Provider Pricing: USD 5846.00,
Conference + Novel CNS Biomarker Day - Service Provider Pricing: USD 5846.00,
Conference Only - Service Provider Pricing: USD 3599.00


Speakers: Rachel Angers Associate Director, Neurodegeneration UCB, Sandra Banack Senior Scientist Brain Chemistry Labs, Habib Baghirov Scientific Lead Roche, Jay Barth Executive Vice President and Chief, Medical Officer Lexeo Therapeutics, Karen He Scientist, Disease Genetics Janssen, Tien Dam Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders Biogen, Cheng Fang Senior Vice President, Research and Development Annovis Bio, Sarah Huntwork-Rodriguez Associate Director, Biomarkers Denali Therapeutics Inc., and more.

Categoría: Eventos ›
Subcategoría: Otros Eventos ›
Contacte al anunciante